GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CF PharmTech 2652.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

5.04

-2.33%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CF PharmTech

Its shares trade on HKEX under the ticker 2652.HK. It has been listed since 8 October 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥432.5m and net income of CN¥2.5m. At that date it held total assets of CN¥1.78bn and shareholders' equity of CN¥1.47bn.

CF PharmTech, Inc engages in the research, development, production and sale of respiratory diseases pharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2025-10-08. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The firm's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The firm mainly conducts its business in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
8 Oct 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Suzhou, Jiangsu with a focus on respiratory disease pharmaceutical products.
  • IPO scheduled for 2025-10-08 providing potential capital for growth.
  • Product portfolio includes CF017 for asthma and CF018 for allergic rhinitis.

Weaknesses

  • Sector and industry classifications are listed as N/A, indicating unclear market positioning.
  • Business primarily conducted in the domestic market, limiting international expansion potential.
  • No specific details on research and development capabilities or production capacity provided.

Opportunities

  • Growing demand for respiratory disease treatments in the domestic market.
  • Potential for international market expansion beyond the domestic focus.
  • IPO in 2025-10-08 could attract investment for product development.

Threats

  • Unspecified competition in the respiratory disease pharmaceutical sector.
  • Dependence on domestic market may limit growth if domestic demand declines.
  • IPO date is in the future, creating uncertainty around capital availability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.